MedTrace Logo

The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy

NCT07360002 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2026-01-22

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if Shenqi Yishen Granules works to treat IgA Nephropathy in adults. It will also learn about the safety of Shenqi Yishen Granules. The main questions it aims to answer are:

Does Shenqi Yishen Granules lower 24-hour urinary protein quantification of participants? What medical problems do participants have when taking Shenqi Yishen Granules? Researchers will compare Shenqi Yishen Granules to a placebo (a look-alike substance that contains no drug) to see if Shenqi Yishen Granules works to treat IgA Nephropathy.

Conditions

  • IgA Nephropathy (IgAN)

Interventions

DRUG

Shenqi Yishen Granules

A traditional Chinese medicine compound for the treatment of IgA nephropathy

DRUG

Placebo

a look-alike substance that contains no drug

Sponsors & Collaborators

  • The First Affiliated Hospital of Zhejiang Chinese Medical University

    collaborator OTHER

  • The Second Affiliated Hospital of Zhejiang Chinese Medical University

    collaborator OTHER

  • Red Cross Hospital, Hangzhou, China

    collaborator OTHER

  • Hangzhou Traditional Chinese Medicine Hospital

    collaborator UNKNOWN

  • Zhenhai District Traditional Chinese Medicine Hospital

    collaborator UNKNOWN

  • Jiangsu Provincial Hospital of Traditional Chinese Medicine

    collaborator UNKNOWN

  • Shao Yifu Hospital of Zhejiang Medical University

    collaborator UNKNOWN

  • Hangzhou First People's Hospital, School of Medicine, Zhejiang Universiry

    collaborator UNKNOWN

  • Yuyao City Traditional Chinese Medicine Hospital

    collaborator UNKNOWN

  • First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

    collaborator UNKNOWN

  • Affiliated Hospital of Jiaxing University

    collaborator OTHER

  • Hangzhou Xiaoshan First People's Hospital

    collaborator UNKNOWN

  • Shanghai 6th People's Hospital

    collaborator OTHER

  • Keda Lu

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2026-12-31
Completion
2026-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07360002 on ClinicalTrials.gov